Opioid-Related DisordersNCT00000262
Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14
A study testing 30% Nitrous oxide, 0.4% Sevoflurane and 0.2% sevoflurane in people with Opioid-Related Disorders and Substance-Related Disorders, run by University of Chicago at 1 site in United States.
Trial summary
The purpose of this study is to determine the effects of combined sevoflurane and nitrous oxide inhalation on mood, psychomotor performance, and the pain response in humans. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Opioid-Related Disorders, Substance-Related Disorders
- What is being tested?
- 30% Nitrous oxide, 0.4% Sevoflurane and 0.2% sevoflurane
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 1996to Feb 1999
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Please contact site for information.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Chicago, Anesthesia & Critical Care
Chicago, Illinois, 60637
About this study
Official title: Effects of Combined Sevoflurane and Nitrous Oxide Inhalation
The purpose of this study is to determine the effects of combined sevoflurane and nitrous oxide inhalation on mood, psychomotor performance, and the pain response in humans.
- Being tested
- 30% Nitrous oxide, 0.4% Sevoflurane, 0.2% sevoflurane, Placebo
- Keywords
- nitrous oxide, sevoflurane, drug interaction, subjective effects, analgesia, healthy volunteers
- Medical subject headings
- Opioid-Related Disorders, Substance-Related Disorders, Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
30% Nitrous oxideDrug
0.4% SevofluraneDrug
0.2% sevofluraneDrug
PlaceboOther
| Study group | Role | What they receive |
|---|---|---|
| Placebo +/- 30% Nitrous oxide | Placebo comparator | Not described Receives: Drug: 30% Nitrous oxide; Other: Placebo |
| Sevoflurane 0.2% +/- 30% Nitrous oxide | Active comparator | Not described Receives: Drug: 30% Nitrous oxide; Drug: 0.2% sevoflurane |
| Sevoflurane 0.4% +/- 30% Nitrous oxide | Active comparator | Not described Receives: Drug: 30% Nitrous oxide; Drug: 0.4% Sevoflurane |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain intensity, pain bothersomeness
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Measured: During inhalation
Mood
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Measured: During inhalation
Psychomotor performance
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Measured: During inhalation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 1999 (estimated)
- Study startNov 1996
- Primary completionFeb 1999
- Study completionFeb 1999
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Opioid-Related DisordersStudies of the same condition, open and under way.
- More trials run by University of ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Responsible party
- Sponsor
- Investigators
- James Zacny, Ph.D., Principal investigator, University of Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00000262
- Sponsor's protocol ID
- NIDA-08391-14
- Other IDs
- R01DA008391, R01-08391-14
- Status last verified
- May 2015
- First submitted
- 20 Sep 1999
- Last updated
- 27 May 2015
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Combined Sevoflurane and Nitrous Oxide Inhalation
- ClinicalTrials.gov ID
- NCT00000262
- Acronym / sponsor ID
- NIDA-08391-14
- Keywords
- nitrous oxide, sevoflurane, drug interaction, subjective effects, analgesia, healthy volunteers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University of ChicagoUniversity, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Study start
- Nov 1996
- Primary completion
- Feb 1999 (actual)
- Study completion
- Feb 1999 (actual)
- First posted
- 21 Sep 1999 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the effects of combined sevoflurane and nitrous oxide inhalation on mood, psychomotor performance, and the pain response in humans.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Placebo +/- 30% Nitrous oxide | Placebo comparator | Drug: 30% Nitrous oxide, Other: Placebo |
| Sevoflurane 0.2% +/- 30% Nitrous oxide | Active comparator | Drug: 30% Nitrous oxide, Drug: 0.2% sevoflurane |
| Sevoflurane 0.4% +/- 30% Nitrous oxide | Active comparator | Drug: 30% Nitrous oxide, Drug: 0.4% Sevoflurane |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 30% Nitrous oxide | Drug | Placebo +/- 30% Nitrous oxide, Sevoflurane 0.2% +/- 30% Nitrous oxide, Sevoflurane 0.4% +/- 30% Nitrous oxide |
| 0.4% Sevoflurane | Drug | Sevoflurane 0.4% +/- 30% Nitrous oxide |
| 0.2% sevoflurane | Drug | Sevoflurane 0.2% +/- 30% Nitrous oxide |
| Placebo | Other | Placebo +/- 30% Nitrous oxide |
Primary outcome
Pain intensity, pain bothersomeness
Time frame: During inhalation
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Mood
Time frame: During inhalation
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Psychomotor performance
Time frame: During inhalation
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2015.
Related trials for Opioid-Related Disorders
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Active, not recruitingPhase 2
Wellcome Leap Psilocybin for OUD
Opioid Use Disorder
Recruiting
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
Opioid Use Disorder, Opioid Misuse
Active, not recruiting
EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy
Substance Use Disorders, Opioid Use Disorder, Severe
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James Zacny, Ph.D. principal investigator
University of Chicago
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 30% Nitrous oxide, 0.4% Sevoflurane and 0.2% sevoflurane in people with Opioid-Related Disorders and Substance-Related Disorders, run by University of Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 May 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain intensity, pain bothersomeness (time frame: During inhalation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2015.